Gain Therapeutics reported earnings of -$ 0.07 per GANX share on Nov 10, 2026, falling short of analysts' expectations by
| Report Date | Nov 10, 2026 |
|---|---|
| Forecasted EPS | -$ 0.12 |
| Earnings Per Share (Surprise) | -$ 0.07 (+$ 0.0546) |
| Last Year's EPS | -$ 0.15 |
| EPS YoY Change |
Out of the last 34 earnings reporting periods, Gain Therapeutics beat analysts’ expectations 12 times and fell short of expectations 8 time(s). Gain Therapeutics reported earnings per share of -$ 0.07 in the last report surpassing an estimated EPS of -$ 0.12 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.12 | -$ 0.07 | -$ 0.15 | |
| Aug 11, 2026 | -$ 0.14 | -$ 0.11 | -$ 0.19 | |
| May 11, 2026 | -$ 0.13 | -$ 0.13 | -$ 0.16 | |
| Mar 26, 2026 | -$ 0.14 | -$ 0.11 | -$ 0.11 | |
| Nov 12, 2025 | -$ 0.15 | -$ 0.15 | -$ 0.17 | |
| Aug 12, 2025 | -$ 0.17 | -$ 0.19 | -$ 0.42 | |
| May 14, 2025 | -$ 0.16 | -$ 0.16 | -$ 0.22 | |
| Mar 27, 2025 | -$ 0.18 | -$ 0.11 | -$ 0.29 | |
| Nov 14, 2024 | -$ 0.23 | -$ 0.17 | -$ 0.37 | |
| Aug 8, 2024 | -$ 0.31 | -$ 0.42 | -$ 0.62 | |
| May 14, 2024 | -$ 0.30 | -$ 0.22 | -$ 0.43 | |
| Mar 26, 2024 | -$ 0.32 | -$ 0.29 | -$ 0.39 | |
| Nov 14, 2023 | -$ 0.47 | -$ 0.37 | -$ 0.38 | |
| Aug 10, 2023 | -$ 0.33 | -$ 0.62 | -$ 0.43 | |
| May 12, 2023 | -$ 0.40 | -$ 0.43 | -$ 0.28 | |
| Mar 23, 2023 | -$ 0.37 | -$ 0.39 | -$ 0.25 | |
| Nov 10, 2022 | -$ 0.46 | -$ 0.38 | -$ 0.39 | |
| Aug 8, 2022 | -$ 0.35 | -$ 0.43 | -$ 0.30 | |
| May 16, 2022 | -$ 0.34 | -$ 0.28 | -$ 0.50 | |
| Mar 24, 2022 | -$ 0.49 | -$ 0.25 | -$ 0.30 |
Gain Therapeutics’s stock was trading at $ 1.09 on Nov 9, 2026 a day before the last earnings report was released.Following the release of the earnings report, GANX’s price increased to $ 1.11 on Nov 11, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.07 | $ 1.09 | $ 1.11 | |
| Aug 11, 2026 | -$ 0.11 | $ 1.77 | $ 2.12 | |
| May 11, 2026 | -$ 0.13 | $ 1.82 | $ 1.80 | |
| Mar 26, 2026 | -$ 0.11 | $ 1.96 | $ 1.83 | |
| Nov 12, 2025 | -$ 0.15 | $ 2.68 | $ 2.99 | |
| Aug 12, 2025 | -$ 0.19 | $ 1.46 | $ 1.55 | |
| May 14, 2025 | -$ 0.16 | $ 1.93 | $ 1.81 | |
| Mar 27, 2025 | -$ 0.11 | $ 2.09 | $ 1.89 | |
| Nov 14, 2024 | -$ 0.17 | $ 2.03 | $ 1.85 | |
| Aug 8, 2024 | -$ 0.42 | $ 0.9525 | $ 0.9814 | |
| May 14, 2024 | -$ 0.22 | $ 2.42 | $ 2.62 | |
| Mar 26, 2024 | -$ 0.29 | $ 3.65 | $ 3.73 | |
| Nov 14, 2023 | -$ 0.37 | $ 2.79 | $ 2.90 | |
| Aug 10, 2023 | -$ 0.62 | $ 3.75 | $ 3.52 | |
| May 12, 2023 | -$ 0.43 | $ 5.15 | $ 5.08 | |
| Mar 23, 2023 | -$ 0.39 | $ 4.91 | $ 4.90 | |
| Nov 10, 2022 | -$ 0.38 | $ 3.07 | $ 3.21 | |
| Aug 8, 2022 | -$ 0.43 | $ 4.01 | $ 3.99 | |
| May 16, 2022 | -$ 0.28 | $ 2.67 | $ 2.69 | |
| Mar 24, 2022 | -$ 0.25 | $ 4.48 | $ 4.20 |
Gain Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Gain Therapeutics beat analysts’ expectations during the last earnings period by
